犀角地黄汤联合西药对脓毒症凝血功能障碍患者临床疗效、凝血指标及预后的影响
|
摘要
目的:探讨脓毒症凝血功能障碍患者采用犀角地黄汤联合西药治疗对其凝血指标、临床疗效的影响,并对患者的预后情况进行分析。方法:随机选取2016年5月-2018年6月来本院接受治疗的脓毒症凝血功能障碍患者48例作为此次临床研究对象,根据治疗方法将其分为对照组和观察组,每组各24例。对照组采用单纯西药治疗,观察组采用犀角地黄汤联合西药治疗,观察两组凝血指标、临床疗效、生活质量及对治疗的满意度。结果:治疗前,两组凝血指标比较,差异均无统计学意义(P>0.05);治疗后,观察组PLT和FIB水平均明显高于对照组,PT和APTT均明显短于对照组,D-D水平明显低于对照组,差异均有统计学意义(P<0.05)。观察组临床治疗效果、生活质量及对治疗的满意度和对照组相比,差异均有统计学意义(P<0.05)。结论:脓毒症凝血功能障碍患者采用犀角地黄汤联合西药治疗可明显改善患者的凝血指标,提高临床疗效和生活质量,从而提高其对治疗的满意度。
Objective:To investigate the effect of Xijiao Dihuang Decoction combined with western medicine on coagulation index and clinical efficacy of sepsis patients with coagulation dysfunction,and to analyze the prognosis of patients.Method:A total of 48 sepsis patients with coagulation dysfunction who treated in our hospital from May 2016 to June 2018 were randomly selected as the experimental subjects in this clinical study.According to different clinical treatment methods,they were divided into two groups,24 cases in each group.The patients in the control group were treated with simple western medicine,the patients in the observation group were treated with Xijiao Dihuang Decoction combined with western medicine.The coagulation index,clinical efficacy,quality of life and satisfaction with treatment of two groups were observed.Result:Before treatment,there were no significant differences in coagulation indexes between two groups(P>0.05).After treatment,the levels of PLT and FIB in the observation group were significantly higher than those in the control group,and PT and APTT were significantly shorter than those of the control group,the level of D-D was significantly lower than that of the control group,and the differences were statistically significant(P<0.05).The clinical treatment effect,quality of life and satisfaction of treatment in the observation group compared with the control group were statistically significant(P<0.05).Conclusion:Xijiao Dihuang Decoction combined with western medicine can significantly improve the coagulation indexes,clinical efficacy and quality of life of sepsis patients with coagulation dysfunction,so as to improve their satisfaction with the treatment.
Objective:To investigate the effect of Xijiao Dihuang Decoction combined with western medicine on coagulation index and clinical efficacy of sepsis patients with coagulation dysfunction,and to analyze the prognosis of patients.Method:A total of 48 sepsis patients with coagulation dysfunction who treated in our hospital from May 2016 to June 2018 were randomly selected as the experimental subjects in this clinical study.According to different clinical treatment methods,they were divided into two groups,24 cases in each group.The patients in the control group were treated with simple western medicine,the patients in the observation group were treated with Xijiao Dihuang Decoction combined with western medicine.The coagulation index,clinical efficacy,quality of life and satisfaction with treatment of two groups were observed.Result:Before treatment,there were no significant differences in coagulation indexes between two groups(P>0.05).After treatment,the levels of PLT and FIB in the observation group were significantly higher than those in the control group,and PT and APTT were significantly shorter than those of the control group,the level of D-D was significantly lower than that of the control group,and the differences were statistically significant(P<0.05).The clinical treatment effect,quality of life and satisfaction of treatment in the observation group compared with the control group were statistically significant(P<0.05).Conclusion:Xijiao Dihuang Decoction combined with western medicine can significantly improve the coagulation indexes,clinical efficacy and quality of life of sepsis patients with coagulation dysfunction,so as to improve their satisfaction with the treatment.
引文
[1]王淑颖,应春晓,何许伟,等.乌司他丁对ICU脓毒症患者凝血功能障碍的影响[J].中国药房,2015,26(29):4094-4096.
[2]李秋实.美罗培南治疗新生儿重症多重耐药菌感染临床研究[J].中国药业,2017,26(2):60-63.
[3]张艺森.美罗培南结合替加环素治疗新生儿重症多重耐药菌感染的疗效观察[J].北方药学,2017,14(12):108-109.
[4]代文利.美罗培南治疗新生儿重症细菌感染临床效果评价[J].中国伤残医学,2016,24(3):127-128.
[5]马金权.美罗培南结合替加环素治疗新生儿重症多重耐药菌感染的效果观察[J].中国继续医学教育,2015,7(11):215-216.
[6]谢朝云,熊芸,孙静,等.新生儿重症监护病房多重耐药菌感染危险因素logistic回归分析[J].临床儿科杂志,2016,34(9):641-644.
[7]简于群,单志红.美罗培南联合替加环素治疗新生儿重症多重耐药菌感染的临床效果[J].临床合理用药杂志,2015,8(27):12-13.
[8]李卜武,朱宏,罗文朝,等.替加环素辅助治疗ICU患者多重耐药菌感染临床效果探讨[J].实用药物与临床,2015,18(5):567-570.
[9]简于群.美罗培南联合替加环素治疗新生儿重症多重耐药菌感染的临床效果[J].临床合理用药,2015,8(9C):12-14.
[10]徐康,邵华,于锋,等.替加环素治疗多重耐药菌感染重症肺炎的研究进展[J].中国抗生素杂志,2016,41(8):577-583.
[11]魏捷,张冬梅,吕菁君,等.119例脓毒症凝血、抗凝和纤溶功能的临床研究[J].中华急诊医学杂志,2018,27(8):905-911.
[12]王曦,罗丽玲,李晓莉.高原地区新生儿多药耐药菌感染的临床特点及控制研究[J].中华医院感染学杂志,2015,25(5):1178-1180.
[13]Costello S E,Gales A C,Morfn-Otero R,et al.Mechanisms of resistance,clonal expansion,and increasing prevalence of Acinetobacter baumannii strains displaying elevated tigecycline MIC values in Latin America[J].Microb Drug Resist,2015,22(4):253-258.
[14]阿不都热合曼·阿布都卡地尔.替加环素辅助治疗ICU患者多重耐药菌感染的临床效果及安全性[J].世界最新医学信息文摘,2016,16(96):146-147.
[15]刘英丽,李派,刘剑波.替加环素治疗多重耐药菌肺部感染的临床观察[J].临床肺科杂志,2016,21(11):1993-1995.
[16]周之昊.美罗培南联合替加环素治疗新生儿重症多重耐药菌感染的临床效果及安全性[J].中国药物经济学,2017(7):66-68.
[17]宋立成,韩志海.脓毒症相关凝血功能障碍机制及治疗的研究进展[J].中华危重症医学杂志,2017,10(2):125-129.
[18]周立伟.前瞻性评价中国新的弥散性血管内凝血诊断积分系统[D].济南:山东大学,2016.
[19]巩美鱼,刘保社,段淑琴,等.脓毒症凝血功能障碍患者中医证型与预后相关性研究[J].中国中医急症,2016,25(10):1934-1936.
[20]张默,李敏珠,鲁俊,等.犀角地黄汤治疗老年脓毒症患者的临床研究[J].中国中西医结合急救杂志,2017,24(4):359-363.
[2]李秋实.美罗培南治疗新生儿重症多重耐药菌感染临床研究[J].中国药业,2017,26(2):60-63.
[3]张艺森.美罗培南结合替加环素治疗新生儿重症多重耐药菌感染的疗效观察[J].北方药学,2017,14(12):108-109.
[4]代文利.美罗培南治疗新生儿重症细菌感染临床效果评价[J].中国伤残医学,2016,24(3):127-128.
[5]马金权.美罗培南结合替加环素治疗新生儿重症多重耐药菌感染的效果观察[J].中国继续医学教育,2015,7(11):215-216.
[6]谢朝云,熊芸,孙静,等.新生儿重症监护病房多重耐药菌感染危险因素logistic回归分析[J].临床儿科杂志,2016,34(9):641-644.
[7]简于群,单志红.美罗培南联合替加环素治疗新生儿重症多重耐药菌感染的临床效果[J].临床合理用药杂志,2015,8(27):12-13.
[8]李卜武,朱宏,罗文朝,等.替加环素辅助治疗ICU患者多重耐药菌感染临床效果探讨[J].实用药物与临床,2015,18(5):567-570.
[9]简于群.美罗培南联合替加环素治疗新生儿重症多重耐药菌感染的临床效果[J].临床合理用药,2015,8(9C):12-14.
[10]徐康,邵华,于锋,等.替加环素治疗多重耐药菌感染重症肺炎的研究进展[J].中国抗生素杂志,2016,41(8):577-583.
[11]魏捷,张冬梅,吕菁君,等.119例脓毒症凝血、抗凝和纤溶功能的临床研究[J].中华急诊医学杂志,2018,27(8):905-911.
[12]王曦,罗丽玲,李晓莉.高原地区新生儿多药耐药菌感染的临床特点及控制研究[J].中华医院感染学杂志,2015,25(5):1178-1180.
[13]Costello S E,Gales A C,Morfn-Otero R,et al.Mechanisms of resistance,clonal expansion,and increasing prevalence of Acinetobacter baumannii strains displaying elevated tigecycline MIC values in Latin America[J].Microb Drug Resist,2015,22(4):253-258.
[14]阿不都热合曼·阿布都卡地尔.替加环素辅助治疗ICU患者多重耐药菌感染的临床效果及安全性[J].世界最新医学信息文摘,2016,16(96):146-147.
[15]刘英丽,李派,刘剑波.替加环素治疗多重耐药菌肺部感染的临床观察[J].临床肺科杂志,2016,21(11):1993-1995.
[16]周之昊.美罗培南联合替加环素治疗新生儿重症多重耐药菌感染的临床效果及安全性[J].中国药物经济学,2017(7):66-68.
[17]宋立成,韩志海.脓毒症相关凝血功能障碍机制及治疗的研究进展[J].中华危重症医学杂志,2017,10(2):125-129.
[18]周立伟.前瞻性评价中国新的弥散性血管内凝血诊断积分系统[D].济南:山东大学,2016.
[19]巩美鱼,刘保社,段淑琴,等.脓毒症凝血功能障碍患者中医证型与预后相关性研究[J].中国中医急症,2016,25(10):1934-1936.
[20]张默,李敏珠,鲁俊,等.犀角地黄汤治疗老年脓毒症患者的临床研究[J].中国中西医结合急救杂志,2017,24(4):359-363.